Dementia Resistance Genes
Quick Facts
Why do some people resist dementia despite high genetic risk?
Dementia is a major global health burden. The World Health Organization estimates that more than 55 million people live with the condition worldwide, and Alzheimer's disease is the most common cause. For decades, genetics research concentrated on what raises risk. The best-known example is the APOE4 allele, which substantially increases the likelihood of late-onset Alzheimer's disease, while the less common APOE2 allele is associated with lower risk.
A complementary approach studies the exceptions: people whose brains show substantial Alzheimer's pathology, or who carry mutations that would normally cause early-onset disease, yet who remain cognitively intact for years longer than expected. Researchers call this resilience or resistance. Because these individuals appear to have natural defenses, understanding how those defenses work could point to treatments that mimic them. The logic mirrors how studying people with naturally low LDL cholesterol led to PCSK9-inhibiting drugs.
Which protective gene variants have scientists identified so far?
In a 2019 report in Nature Medicine, Arboleda-Velasquez and colleagues described a woman from a large Colombian kindred carrying the PSEN1 E280A mutation, which typically causes mild cognitive impairment in the mid-40s and dementia in the 50s. She remained cognitively intact until her 70s. She was also homozygous for a rare APOE3 variant called Christchurch, which was proposed as a protective factor. Imaging showed heavy amyloid burden but relatively limited tau pathology in memory-related brain regions, suggesting the variant might interrupt the link between amyloid and downstream neurodegeneration.
A 2023 Nature Medicine case report by Lopera and colleagues described a man from the same family who was also expected to develop early dementia but stayed functionally intact until his 60s. He carried a rare variant in the Reelin gene, known as COLBOS, which is thought to enhance Reelin signaling and reduce tau phosphorylation. These are single-case observations, so they cannot establish cause, but they have attracted research interest because they involve pathways that could be targeted by drugs. Researchers are also studying genetic and non-genetic resilience factors in larger cohorts, which may reveal more common variants with smaller effects.
Could resistance genes lead to new dementia treatments, and what should patients know?
The main promise of resistance genetics is target discovery. If enhancing Reelin signaling or mimicking the Christchurch effect on APOE biology can slow tau-related damage, scientists could develop antibodies, gene therapies or small molecules that reproduce it. Early-stage preclinical work is exploring these ideas, but translating a rare variant observed in a few people into a safe therapy for broad populations is difficult and often fails. Recent experience with Alzheimer's drug development shows that biological plausibility does not guarantee clinical benefit.
For patients and families, the practical takeaway is that genes are not destiny. Most dementia is multifactorial, and the Lancet Commission on dementia has estimated that a substantial share of cases, roughly 40 percent in its 2024 update, may be linked to modifiable risk factors such as hypertension, hearing loss, physical inactivity, smoking, diabetes and social isolation. Genetic testing for APOE is not routinely recommended for the general public, and anyone considering it should discuss the implications with a clinician or genetic counselor.
Frequently Asked Questions
No. APOE4 raises risk, particularly in people with two copies, but many carriers never develop dementia and many people with dementia do not carry it. Other genes, vascular health and lifestyle all contribute.
Rare protective variants such as Christchurch and Reelin-COLBOS are research findings, not routine clinical tests. APOE testing is available but is generally not recommended for people without a specific clinical reason.
Evidence supports managing blood pressure, staying physically active, treating hearing loss, not smoking, controlling diabetes, and staying socially and mentally engaged. These measures lower risk but cannot guarantee prevention.
References
- World Health Organization. Dementia fact sheet.
- Arboleda-Velasquez JF, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine. 2019.
- Lopera F, et al. Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man. Nature Medicine. 2023.
- Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024.
- Nature. Some people are resistant to dementia — here's what their genes can teach us. News feature, 2026.